An MIT pro­fes­sor's rare dis­ease quest rip­ples through­out biotech

Last month
People
In Focus

Af­ter Roe, star­tups seek to fill Big Phar­ma’s male con­tra­cep­tion gap

Last month
Startups
In Focus

Ex­clu­sive: UPMC launch­es an­oth­er biotech, root­ed in the tu­mor mi­croen­vi­ron­ment

Last month
Financing
Startups

What can Mer­ck af­ford to buy now? ‘ANY­THING’ it wants

Last month
Deals
Bioregnum

Q&A: CMO and de­vel­op­ment chief Di­et­mar Berg­er says Sanofi is 'right there at the table' on di­ver­si­ty ef­forts

2 months ago
Pharma
Marketing

'Go quick­ly': Am­gen R&D vet Dirk Nagors­en jumps to a start­up with big plans for TCRs

2 months ago
People
R&D

Ex­clu­sive: Turnover tsuna­mi at FDA's phar­ma in­spec­tions of­fice puts the back­log in sharp fo­cus

2 months ago
FDA+

The new CEO at Roche has fol­lowed a fa­mil­iar path in­to the C-suite. But it's his next steps that are cru­cial to his suc­cess

2 months ago
Bioregnum

FDA+ roundup: New draft guid­ance on ther­a­peu­tic equiv­a­lence; Cavaz­zoni talks ac­cel­er­at­ed ap­provals

2 months ago
FDA+

Scoop: Ab­b­Vie ter­mi­nates ear­ly-stage study of I-Mab's an­ti­body, an­oth­er clin­i­cal set­back in CD47 field

2 months ago
R&D
China

Ex­clu­sive: Mark Pruzan­s­ki is once again reach­ing for the brass ring in biotech

2 months ago
Startups
Bioregnum

Phar­mas change up lo­gos in June to sig­nal LGT­BQ+ sol­i­dar­i­ty, but ex­perts call for push be­yond ‘rain­bow wash­ing’

2 months ago
Pharma
Marketing

Af­ter abor­tion rul­ing, biotechs be­hind nov­el con­tra­cep­tives say tide is turn­ing on in­sur­ance cov­er­age

2 months ago
In Focus

Black­Rock joins An­drew Lo's risk analy­sis firm to search for odds-on biotech bets in tur­bu­lent times

2 months ago
Deals
Bioregnum

DNA se­quenc­ing gi­ant Il­lu­mi­na bat­tles an­titrust reg­u­la­tors and grow­ing com­pe­ti­tion

2 months ago
Pharma
In Focus

#BIO22: De­cen­tral­ized tri­als

2 months ago

#BIO22: Fire­side chat with Zachary Bren­nan and Ian Thomp­son

2 months ago

Fa­heem Has­nain forges a $120M pri­vate place­ment. So what did we learn from that?

2 months ago
Deals
Bioregnum

#DIA22: Re­vamp­ing the FDA's prized ac­cel­er­at­ed ap­provals

2 months ago

#DIA22: Fire­side chat with Zachary Bren­nan and Aaron Kessel­heim

2 months ago

No sur­ren­der: A group of mar­quee biotech play­ers bets on the $350M PhI­II res­ur­rec­tion sto­ry of a heavy­weight con­tender

2 months ago
Deals
Bioregnum

A por­trait of a biotech buy­out deal in sav­age times: turn­ing a $15.50 of­fer in­to a $7.12 deal

2 months ago
Deals
Bioregnum

The 2022 End­points 11 is com­ing. Do you know a biotech that should be on the list?

2 months ago
Bioregnum

#BIO22: Fire­side Chat with John Car­roll & Stéphane Ban­cel; 'No­body needs the type of wealth that we have'

2 months ago
First page Previous page 12345 Next page Last page